08045804946
medisus.pharma007@gmail.com
भाषा बदलें
Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion
Bevacizumab Concentrate For Solution For Infusion
Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion Bevacizumab Concentrate For Solution For Infusion

Bevacizumab Concentrate For Solution For Infusion

उत्पाद विवरण:

X

मूल्य और मात्रा

  • 5

व्यापार सूचना

  • प्रति सप्ताह
  • दिन

उत्पाद वर्णन

Bevacizumab concentrate for solution for infusion, with a strength of 400 mg/16 mL, is a medication used in the treatment of various types of cancer. Here's an overview of its use:


1. Colorectal Cancer Bevacizumab is approved for use in combination with chemotherapy for the treatment of metastatic colorectal cancer (CRC). It is typically used in combination with a fluoropyrimidine-based chemotherapy regimen (such as FOLFOX or FOLFIRI).


2. Lung Cancer Bevacizumab is also used in the treatment of non-small cell lung cancer (NSCLC), specifically in combination with chemotherapy for the treatment of advanced, metastatic, or recurrent NSCLC. It may be used in patients who have not received prior chemotherapy for metastatic disease.


3. Breast Cancer Bevacizumab may be used in combination with chemotherapy for the treatment of metastatic breast cancer, particularly in cases where the cancer is HER2-negative.


4. Renal Cell Carcinoma Bevacizumab, in combination with interferon alfa, is used for the treatment of metastatic renal cell carcinoma (kidney cancer).


Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels that supply tumors with oxygen and nutrients. By inhibiting VEGF, bevacizumab helps to disrupt the blood supply to tumors, thereby slowing their growth and reducing their ability to spread.


The concentration of 400 mg/16 mL indicates that each mL of the solution contains 25 mg of bevacizumab. This solution is typically diluted further and administered as an intravenous infusion over a period of time specified by a healthcare professional.


Common side effects of bevacizumab may include hypertension (high blood pressure), proteinuria (protein in the urine), bleeding, gastrointestinal perforation, impaired wound healing, and increased risk of blood clots. It's important for patients to be monitored closely by their healthcare provider while receiving bevacizumab to manage any side effects and ensure the treatment remains effective.


As with any cancer treatment, it's crucial to discuss the potential benefits and risks with a healthcare professional to make informed decisions about treatment options.

क्रय आवश्यकता विवरण दर्ज करें
ईमेल आईडी
मोबाइल नंबर

Oncology Drugs & Injections अन्य उत्पाद



Back to top